Centessa Pharmaceuticals (CNTA) Short term Debt (2020)

Centessa Pharmaceuticals (CNTA) reported Short term Debt of $913000.0 for Q4 2020.

Centessa Pharmaceuticals (CNTA) has 1 years of Short term Debt data on file, last reported at $913000.0 in Q4 2020.

  • Quarterly Short term Debt changed N/A year-over-year to $913000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $913000.0 (changed N/A YoY) and the FY2020 annual result came in at $913000.0, changed N/A from the prior year.
  • Short term Debt steadied at $913000.0 in Q4 2020 per CNTA's latest filing.
  • Across five years, Short term Debt topped out at $913000.0 in Q4 2020 and bottomed at $913000.0 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Centessa Pharmaceuticals 6.12 Bn 6.12 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 913,000.00